[Additional treatment with Esberitox N in patients with chemo-radiotherapy treatment of advanced breast cancer].

A study was made at random on 70 female patients with advanced mamma carcinoma to find out whether an additional treatment with Esberitox N prevents or diminishes the sideeffects of a combined chemo-radiation therapy. As it could not be excluded that the efficacy of Esberitox N on previous affliction by haematotoxic therapy would probably differ, the study was made on various groups of risk. The parameter to form an opinion were either the peripheral hematosis or the appearance of infections.

[Supplementary treatment with Esberitox of female patients undergoing curative adjuvant irradiation following breast cancer].

1. The study was supposed to investigate a possible prevention or reduction of the toxicity of radiotherapy by an additional treatment with Esberitox. This question arose when performing an investigation about the effect of Esberitox in a combined chemo-radiotherapy.

[Effect of fractionation on the immunosuppressive effect of total lymphatic irradiation (TLI)].

The influence of single dose and fractionation on the immunosuppressive effect of a total lymphoid irradiation (TLI) was investigated by experimentation on animals and compared to literature. Lewis rats were irradiated with a constant temporal dose distribution. The weekly dose of 7,0 Gy was fractionated into 1 X 7,0 Gy, 2 X 3,5 Gy and 7 X 1,0 Gy, with rising total doses.

[Adjuvant therapy in breast cancer (high risk). Randomized study: radiotherapy versus combination radiotherapy and chemotherapy].

108 patients with high risk stage of a mammary carcinoma (four or more positive axillary lymph nodes) were submitted after surgery to a prospectively randomized study: a postirradiation in three series with additional administration of tamoxifen was opposed to a reduced-dose irradiation and subsequent simultaneous combination of polychemotherapy and irradiation. In patients with an age of less than 50 years, the combination of chemotherapy and radiotherapy caused a significant prolongation of the recurrence-free interval (greater than 57 months versus 12,75 months). The comparison with literature shows that an average interval of 39.